TWD 52.1
(-1.14%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 3.87 Billion TWD | -10.55% |
2022 | 980.97 Million TWD | -9.89% |
2021 | 1.9 Billion TWD | 22.55% |
2020 | 3.47 Billion TWD | 16.37% |
2019 | 2.73 Billion TWD | -9.52% |
2018 | 2.75 Billion TWD | 45.08% |
2017 | 2.03 Billion TWD | 240.06% |
2016 | 848.08 Million TWD | -76.31% |
2015 | 3.29 Billion TWD | -7.84% |
2014 | 3.57 Billion TWD | 18.52% |
2013 | 3.01 Billion TWD | 85.27% |
2012 | 2.01 Billion TWD | 48.25% |
2011 | 681.08 Million TWD | -7.5% |
2010 | 1.07 Billion TWD | -43.34% |
2009 | 2.02 Billion TWD | -53.53% |
2008 | 3.76 Billion TWD | -4.45% |
2007 | 4.73 Billion TWD | 40.49% |
2006 | 4.73 Billion TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 474.54 Million TWD | 403.82% |
2024 Q2 | 595.06 Million TWD | 27.99% |
2023 Q4 | 495.35 Million TWD | -52.99% |
2023 FY | - TWD | -10.55% |
2023 Q1 | 949.05 Million TWD | 7.11% |
2023 Q2 | 3.08 Billion TWD | 224.6% |
2023 Q3 | 1.05 Billion TWD | -65.8% |
2022 Q1 | 1.26 Billion TWD | 7.33% |
2022 FY | - TWD | -9.89% |
2022 Q4 | 886.06 Million TWD | -17.71% |
2022 Q3 | 1.07 Billion TWD | -13.75% |
2022 Q2 | 1.24 Billion TWD | -1.09% |
2021 Q3 | 1.27 Billion TWD | 0.31% |
2021 Q2 | 1.27 Billion TWD | 3.01% |
2021 FY | - TWD | 22.55% |
2021 Q1 | 1.23 Billion TWD | 68.88% |
2021 Q4 | 1.17 Billion TWD | -7.97% |
2020 Q3 | 888.13 Million TWD | 20.19% |
2020 Q4 | 732.23 Million TWD | -17.55% |
2020 Q1 | 1.69 Billion TWD | 95.3% |
2020 Q2 | 738.93 Million TWD | -56.32% |
2020 FY | - TWD | 16.37% |
2019 Q1 | 919.95 Million TWD | -22.49% |
2019 Q3 | 814.13 Million TWD | -7.55% |
2019 Q4 | 866.12 Million TWD | 6.39% |
2019 FY | - TWD | -9.52% |
2019 Q2 | 880.63 Million TWD | -4.27% |
2018 Q2 | 1 Billion TWD | 38.75% |
2018 Q4 | 1.18 Billion TWD | 27.76% |
2018 FY | - TWD | 45.08% |
2018 Q1 | 725 Million TWD | 73.34% |
2018 Q3 | 929.04 Million TWD | -7.65% |
2017 Q1 | 817.06 Million TWD | 334.21% |
2017 FY | - TWD | 240.06% |
2017 Q4 | 418.26 Million TWD | -37.52% |
2017 Q3 | 669.48 Million TWD | -10.36% |
2017 Q2 | 746.87 Million TWD | -8.59% |
2016 Q1 | 279.78 Million TWD | -76.78% |
2016 FY | - TWD | -76.31% |
2016 Q2 | 486.5 Million TWD | 73.88% |
2016 Q3 | 362.32 Million TWD | -25.52% |
2016 Q4 | -348.85 Million TWD | -196.28% |
2015 Q1 | 217.31 Million TWD | -92.12% |
2015 FY | - TWD | -7.84% |
2015 Q4 | 1.2 Billion TWD | -15.01% |
2015 Q3 | 1.41 Billion TWD | 214.06% |
2015 Q2 | 451.4 Million TWD | 107.72% |
2014 Q3 | 301.06 Million TWD | 33.8% |
2014 FY | - TWD | 18.52% |
2014 Q1 | 285.93 Million TWD | 793.55% |
2014 Q2 | 225 Million TWD | -21.31% |
2014 Q4 | 2.75 Billion TWD | 816.52% |
2013 Q3 | 332.48 Million TWD | 179.2% |
2013 Q4 | -41.22 Million TWD | -112.4% |
2013 Q1 | 2.6 Billion TWD | 100.43% |
2013 Q2 | 119.08 Million TWD | -95.43% |
2013 FY | - TWD | 85.27% |
2012 Q4 | 1.29 Billion TWD | 34.56% |
2012 FY | - TWD | 48.25% |
2012 Q1 | 26.04 Million TWD | -90.11% |
2012 Q2 | 834.41 Million TWD | 3103.51% |
2012 Q3 | 965.17 Million TWD | 15.67% |
2011 Q2 | 284.02 Million TWD | -25.41% |
2011 FY | - TWD | -7.5% |
2011 Q4 | 263.42 Million TWD | 56.02% |
2011 Q3 | 168.84 Million TWD | -40.55% |
2011 Q1 | 380.79 Million TWD | 14.94% |
2010 FY | - TWD | -43.34% |
2010 Q4 | 331.3 Million TWD | 24.26% |
2010 Q3 | 266.62 Million TWD | -6.88% |
2010 Q2 | 286.32 Million TWD | -5.11% |
2010 Q1 | 301.76 Million TWD | 0.0% |
2009 FY | - TWD | -53.53% |
2008 FY | - TWD | -4.45% |
2007 FY | - TWD | 40.49% |
2006 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Sinon Corporation | 2.07 Billion TWD | -86.695% |
All Cosmos Bio-Tech Holding Corporation | 305.41 Million TWD | -1170.182% |
CH Biotech R&D Co., Ltd. | 761.55 Million TWD | -409.395% |